Scienture (NASDAQ:SCNX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Scienture (NASDAQ:SCNX) from a hold rating to a sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Scienture has a consensus rating of “Sell”.

Scienture Trading Up 14.5%

Shares of NASDAQ:SCNX opened at $0.57 on Friday. The firm has a 50 day moving average of $0.71 and a 200-day moving average of $1.08. Scienture has a 12 month low of $0.46 and a 12 month high of $8.15. The stock has a market capitalization of $23.18 million, a PE ratio of -0.57 and a beta of 2.95.

Scienture (NASDAQ:SCNX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter. Scienture had a negative net margin of 10,364.22% and a negative return on equity of 25.18%. The firm had revenue of $0.59 million during the quarter.

About Scienture

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.